4.7 Article

Recent Advances in the Pathophysiology of Asthma

期刊

CHEST
卷 137, 期 6, 页码 1417-1426

出版社

ELSEVIER
DOI: 10.1378/chest.09-1895

关键词

-

资金

  1. European Respiratory Society
  2. AstraZeneca
  3. GlaxoSmithKline
  4. Merck
  5. Wyeth
  6. Schering-Plough
  7. Alexion

向作者/读者索取更多资源

There has been an increased understanding, over the past 2 decades, that asthma is a chronic, immunologically, mediated condition with a disturbance of the normal airway repair mechanism, which results in inflammatory changes and airway remodeling. The airway inflammation and remodeling together likely explain the clinical manifestations of asthma. The mechanisms by which the external environmental cues, together with the complex genetic actions, propagate the inflammatory process that characterize asthma are beginning to be understood. There is also an evolving awareness of the active participation of structural elements, such as the airway epithelium, airway smooth muscle, and endothelium, in this process, in tandem with this has come the realization that inflammatory cells respond in a coordinated, albeit dysfunctional manner, via an array of complex signaling pathways that facilitate communication between these cells; these structural elements within the lung and the bone marrow serve as reservoirs for and the source of inflammatory cells and their precursors. Although often viewed as separate mechanistic entities, so-called innate and acquired immunity often overlap in the propagation of the asthmatic response. This review examines the newer information on the pathophysiologic characteristics of asthma and focuses on papers published over the past 3 years that have helped to improve current levels of understanding. CHEST 2010; 137(6):1417-1426

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据